Nyxoah Reports Q4 and Full Year 2025 Financial and Operational Results: US Commercialization Takes Off, Setting the Stage for Significant Growth in 2026.

Nyxoah, a medical technology company, reported Q4 and FY2025 financial and operational results, with a 347% YoY increase in net sales to $5.6m due to the first full quarter of US commercialization. The company achieved a gross margin of 64% in Q4 and had $48m in cash, equivalents and financial assets at year-end. Since the US launch in August 2025, Nyxoah has trained 145 surgeons and activated 57 accounts, with the Genio system being systematically covered by both private payers and Medicare. The company expects significant growth in 2026.